Label: BOOSTRIX- tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed suspension

  • NDC Code(s): 58160-842-01, 58160-842-05, 58160-842-11, 58160-842-34, view more
    58160-842-43, 58160-842-52
  • Packager: GlaxoSmithKline Biologicals SA
  • Category: VACCINE LABEL
  • DEA Schedule: None
  • Marketing Status: Biologic Licensing Application

Drug Label Information

Updated April 25, 2019

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use BOOSTRIX safely and effectively. See full prescribing information for BOOSTRIX.
    BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) injectable suspension, for intramuscular use
    Initial U.S. Approval: 2005

    INDICATIONS AND USAGE

    BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older. (1)

    DOSAGE AND ADMINISTRATION

    A single intramuscular injection (0.5 mL). (2.2)

    DOSAGE FORMS AND STRENGTHS

    Single-dose vials and single-dose, prefilled syringes containing a 0.5-mL suspension for injection. (3)

    CONTRAINDICATIONS

    Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or to any component of BOOSTRIX. (4.1)
    Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous pertussis antigen-containing vaccine. (4.2)

    WARNINGS AND PRECAUTIONS

    The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions. (5.2)
    If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk of Guillain-Barré syndrome may be increased following a subsequent dose of tetanus toxoid-containing vaccine, including BOOSTRIX. (5.3)
    Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX. (5.4)
    Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive BOOSTRIX unless at least 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine. (5.5)
    Syncope (fainting) can occur in association with administration of injectable vaccines, including BOOSTRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. (5.7)

    ADVERSE REACTIONS

    Common solicited adverse reactions (≥15%) in adolescents (aged 10 to 18 years) were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, and gastrointestinal symptoms. (6.1)
    Common solicited adverse reactions (≥15%) in adults (aged 19 to 64 years) were pain, redness, and swelling at the injection site, headache, fatigue, and gastrointestinal symptoms. (6.1)
    The most common solicited adverse reaction (≥15%) in the elderly (aged 65 years and older) was pain at the injection site. (6.1)

    To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

    DRUG INTERACTIONS

    In subjects aged 11 to 18 years, lower levels for antibodies to pertactin (PRN) were observed when BOOSTRIX was administered concomitantly with meningococcal conjugate vaccine (serogroups A, C, Y, and W-135) as compared with BOOSTRIX administered first. (7.1)
    In subjects aged 19 to 64 years, lower levels for antibodies to filamentous hemagglutinin (FHA) and PRN were observed when BOOSTRIX was administered concomitantly with an inactivated influenza vaccine as compared with BOOSTRIX alone. (7.1)
    Do not mix BOOSTRIX with any other vaccine in the same syringe or vial. (7.1)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 4/2019

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Preparation for Administration

    Shake vigorously to obtain a homogeneous, turbid, white suspension before administration. Do not use if resuspension does not occur with vigorous shaking. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

    For the prefilled syringes, attach a sterile needle and administer intramuscularly.

    For the vials, use a sterile needle and sterile syringe to withdraw the 0.5‑mL dose and administer intramuscularly. Changing needles between drawing vaccine from a vial and injecting it into a recipient is not necessary unless the needle has been damaged or contaminated. Use a separate sterile needle and syringe for each individual.

    Do not administer this product intravenously, intradermally, or subcutaneously.

    2.2 Dose and Schedule

    BOOSTRIX is administered as a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm. There are no data to support repeat administration of BOOSTRIX.

    Five years should elapse between the last dose of the recommended series of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP) or Tetanus and Diphtheria Toxoids, Adsorbed (Td) vaccine and the administration of BOOSTRIX.

    2.3 Additional Dosing Information

    Primary Series

    The use of BOOSTRIX as a primary series or to complete the primary series for diphtheria, tetanus, or pertussis has not been studied.

    Wound Management

    If tetanus prophylaxis is needed for wound management, BOOSTRIX may be given if no previous dose of any Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap) has been administered.

  • 3 DOSAGE FORMS AND STRENGTHS

    BOOSTRIX is a suspension for injection available in 0.5-mL single-dose vials and prefilled TIP-LOK syringes.

  • 4 CONTRAINDICATIONS

    4.1 Hypersensitivity

    A severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or any component of this vaccine is a contraindication to administration of BOOSTRIX [see Description (11)]. Because of the uncertainty as to which component of the vaccine might be responsible, none of the components should be administered. Alternatively, such individuals may be referred to an allergist for evaluation if immunization with any of these components is considered.

    4.2 Encephalopathy

    Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous dose of a pertussis antigen-containing vaccine that is not attributable to another identifiable cause is a contraindication to administration of any pertussis antigen-containing vaccine, including BOOSTRIX.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Prevention and Management of Acute Allergic Reactions

    Prior to administration, the healthcare provider should review the immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions to allow an assessment of benefits and risks. Epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur.

    5.2 Latex

    The tip caps of the prefilled syringes contain natural rubber latex which may cause allergic reactions.

    5.3 Guillain-Barré Syndrome and Brachial Neuritis

    If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk of Guillain-Barré syndrome may be increased following a subsequent dose of tetanus toxoid-containing vaccine, including BOOSTRIX. A review by the Institute of Medicine (IOM) found evidence for a causal relationship between receipt of tetanus toxoid and both brachial neuritis and Guillain-Barré syndrome.1

    5.4 Progressive or Unstable Neurologic Disorders

    Progressive or unstable neurologic conditions (e.g., cerebrovascular events, acute encephalopathic conditions) are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX. It is not known whether administration of BOOSTRIX to persons with an unstable or progressive neurologic disorder might hasten manifestations of the disorder or affect the prognosis. Administration of BOOSTRIX to persons with an unstable or progressive neurologic disorder may result in diagnostic confusion between manifestations of the underlying illness and possible adverse effects of vaccination.

    5.5 Arthus-Type Hypersensitivity

    Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine usually have a high serum tetanus antitoxin level and should not receive BOOSTRIX or other tetanus toxoid-containing vaccines unless at least 10 years have elapsed since the last dose of tetanus toxoid-containing vaccine.

    5.6 Altered Immunocompetence

    As with any vaccine, if administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained.

    5.7 Syncope

    Syncope (fainting) can occur in association with administration of injectable vaccines, including BOOSTRIX. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

    In clinical studies, 4,949 adolescents (aged 10 to 18 years) and 4,076 adults (aged 19 years and older) were vaccinated with a single dose of BOOSTRIX. Of these adolescents, 1,341 were vaccinated with BOOSTRIX in a coadministration study with meningococcal conjugate vaccine [see Drug Interactions (7.1), Clinical Studies (14.5)]. Of these adults, 1,104 were aged 65 years and older [see Clinical Studies (14.4)]. A total of 860 adults aged 19 years and older received concomitant vaccination with BOOSTRIX and influenza vaccines in a coadministration study [see Drug Interactions (7.1), Clinical Studies (14.5)]. An additional 1,092 adolescents aged 10 to 18 years received a non-U.S. formulation of BOOSTRIX (formulated to contain 0.5 mg aluminum per dose) in non-U.S. clinical studies.

    In a randomized, observer-blinded, controlled study in the U.S., 3,080 adolescents aged 10 to 18 years received a single dose of BOOSTRIX and 1,034 received the comparator Td vaccine, manufactured by MassBiologics. There were no substantive differences in demographic characteristics between the vaccine groups. Among recipients of BOOSTRIX and comparator vaccine, approximately 75% were aged 10 to 14 years and approximately 25% were aged 15 to 18 years. Approximately 98% of participants in this study had received the recommended series of 4 or 5 doses of either Diphtheria and Tetanus Toxoids and Pertussis Vaccine Adsorbed (DTwP) or a combination of DTwP and DTaP in childhood. Subjects were monitored for solicited adverse events using standardized diary cards (Days 0-14). Unsolicited adverse events were monitored for the 31-day period following vaccination (Days 0-30). Subjects were also monitored for 6 months post-vaccination for non-routine medical visits, visits to an emergency room, onset of new chronic illness, and serious adverse events. Information regarding late onset adverse events was obtained via a telephone call 6 months following vaccination. At least 97% of subjects completed the 6-month follow-up evaluation.

    In a study conducted in Germany, BOOSTRIX was administered to 319 children aged 10 to 12 years previously vaccinated with 5 doses of acellular pertussis antigen-containing vaccines; 193 of these subjects had previously received 5 doses of INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed). Adverse events were recorded on diary cards during the 15 days following vaccination. Unsolicited adverse events that occurred within 31 days of vaccination (Days 0-30) were recorded on the diary card or verbally reported to the investigator. Subjects were monitored for 6 months post-vaccination for physician office visits, emergency room visits, onset of new chronic illness, and serious adverse events. The 6-month follow-up evaluation, conducted via telephone interview, was completed by 90% of subjects.

    The U.S. adult (aged 19 to 64 years) study, a randomized, observer-blinded study, evaluated the safety of BOOSTRIX (n = 1,522) compared with ADACEL (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) (n = 762), a Tdap vaccine manufactured by Sanofi Pasteur. Vaccines were administered as a single dose. There were no substantive differences in demographic characteristics between the vaccine groups. Subjects were monitored for solicited adverse events using standardized diary cards (Days 0-14). Unsolicited adverse events were monitored for the 31-day period following vaccination (Days 0-30). Subjects were also monitored for 6 months post-vaccination for serious adverse events, visits to an emergency room, hospitalizations, and onset of new chronic illness. Approximately 95% of subjects completed the 6-month follow-up evaluation.

    The U.S. elderly (aged 65 years and older) study, a randomized, observer-blinded study, evaluated the safety of BOOSTRIX (n = 887) compared with DECAVAC (Tetanus and Diphtheria Toxoids Adsorbed) (n = 445), a U.S.-licensed Td vaccine, manufactured by Sanofi Pasteur. Vaccines were administered as a single dose. Among all vaccine recipients, the mean age was approximately 72 years; 54% were female and 95% were white. Subjects were monitored for solicited adverse events using standardized diary cards (Days 0-3). Unsolicited adverse events were monitored for the 31-day period following vaccination (Days 0-30). Subjects were also monitored for 6 months post-vaccination for serious adverse events. Approximately 99% of subjects completed the 6-month follow-up evaluation.

    Solicited Adverse Events in the U.S. Adolescent Study

    Table 1 presents the solicited local adverse reactions and general adverse events within 15 days of vaccination with BOOSTRIX or Td vaccine for the total vaccinated cohort.

    The primary safety endpoint was the incidence of Grade 3 pain (spontaneously painful and/or prevented normal activity) at the injection site within 15 days of vaccination. Grade 3 pain was reported in 4.6% of those who received BOOSTRIX compared with 4.0% of those who received the Td vaccine. The difference in rate of Grade 3 pain was within the pre-defined clinical limit for non-inferiority (upper limit of the 95% CI for the difference [BOOSTRIX minus Td] ≤4%).

    Table 1. Rates of Solicited Local Adverse Reactions or General Adverse Events within the 15-Daya Post-Vaccination Period in Adolescents Aged 10 to 18 Years (Total Vaccinated Cohort)
    Td = Tetanus and Diphtheria Toxoids Adsorbed manufactured by MassBiologics.
    n = Number of subjects in the total vaccinated cohort with local/general symptoms sheets completed.
    Grade 2 = Local: painful when limb moved; General: interfered with normal activity.
    Grade 3 = Local: spontaneously painful and/or prevented normal activity; General: prevented normal activity.
    a Day of vaccination and the next 14 days.
    b Statistically significantly higher (P <0.05) following BOOSTRIX as compared with Td vaccine.
    c Grade 3 injection site pain following BOOSTRIX was not inferior to Td vaccine (upper limit of 2-sided 95% CI for the difference [BOOSTRIX minus Td] in the percentage of subjects ≤4%).
    d Mid-upper region of the vaccinated arm.
    e Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
    f Oral temperatures or axillary temperatures.

    Adverse Reactions/Adverse Events

    BOOSTRIX

    (n = 3,032)

    %

    Td

    (n = 1,013)

    %

    Local

    Pain, anyb

    75.3

    71.7

    Pain, Grade 2 or 3b

    51.2

    42.5

    Pain, Grade 3c

    4.6

    4.0

    Redness, any

    22.5

    19.8

    Redness, >20 mm

    4.1

    3.9

    Redness, ≥50 mm

    1.7

    1.6

    Swelling, any

    21.1

    20.1

    Swelling, >20 mm

    5.3

    4.9

    Swelling, ≥50 mm

    2.5

    3.2

    Arm circumference increase, >5 mmd

    28.3

    29.5

    Arm circumference increase, >20 mmd

    2.0

    2.2

    Arm circumference increase, >40 mmd

    0.5

    0.3

    General

    Headache, any

    43.1

    41.5

    Headache, Grade 2 or 3b

    15.7

    12.7

    Headache, Grade 3

    3.7

    2.7

    Fatigue, any

    37.0

    36.7

    Fatigue, Grade 2 or 3

    14.4

    12.9

    Fatigue, Grade 3

    3.7

    3.2

    Gastrointestinal symptoms, anye

    26.0

    25.8

    Gastrointestinal symptoms, Grade 2 or 3e

    9.8

    9.7

    Gastrointestinal symptoms, Grade 3e

    3.0

    3.2

    Fever, ≥99.5°F (37.5°C)f

    13.5

    13.1

    Fever, >100.4°F (38.0°C)f

    5.0

    4.7

    Fever, >102.2°F (39.0°C)f

    1.4

    1.0

    Unsolicited Adverse Events in the U.S. Adolescent Study

    The incidence of unsolicited adverse events reported in the 31 days after vaccination was comparable between the 2 groups (25.4% and 24.5% for BOOSTRIX and Td vaccine, respectively).

    Solicited Adverse Events in the German Adolescent Study

    presents the rates of solicited local adverse reactions and fever within 15 days of vaccination for those subjects who had previously been vaccinated with 5 doses of INFANRIX. No cases of whole arm swelling were reported. Two individuals (2/193) reported large injection site swelling (range: 110 to 200 mm diameter), in 1 case associated with Grade 3 pain. Neither individual sought medical attention. These episodes were reported to resolve without sequelae within 5 days.

    Table 2. Rates of Solicited Local Adverse Reactions and Fever Reported within the 15-Daya Post-Vaccination Period following Administration of BOOSTRIX in Adolescents Aged 10 to 12 Years Who Had Previously Received 5 Doses of INFANRIX
    INFANRIX = Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed manufactured by GlaxoSmithKline Biologics.
    n = Number of subjects with local/general symptoms sheets completed.
    Grade 2 = Painful when limb moved.
    Grade 3 = Spontaneously painful and/or prevented normal activity.
    a Day of vaccination and the next 14 days.
    b Oral temperatures or axillary temperatures.

    Adverse Reactions and Fever

    BOOSTRIX

    (n = 193)

    %

    Pain, any

    62.2

    Pain, Grade 2 or 3

    33.2

    Pain, Grade 3

    5.7

    Redness, any

    47.7

    Redness, >20 mm

    15.0

    Redness, ≥50 mm

    10.9

    Swelling, any

    38.9

    Swelling, >20 mm

    17.6

    Swelling, ≥50 mm

    14.0

    Fever, ≥99.5°F (37.5°C)b

    8.8

    Fever, >100.4°F (38.0°C)b

    4.1

    Fever, >102.2°F (39.0°C)b

    1.0

    Solicited Adverse Events in the U.S. Adult (Aged 19 to 64 Years) Study

    Table 3 presents solicited local adverse reactions and general adverse events within 15 days of vaccination with BOOSTRIX or the comparator Tdap vaccine for the total vaccinated cohort.

    Table 3. Rates of Solicited Local Adverse Reactions or General Adverse Events within the 15-Daya Post-Vaccination Period in Adults Aged 19 to 64 Years (Total Vaccinated Cohort)
    Tdap = Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, a Tdap vaccine manufactured by Sanofi Pasteur.
    n = Number of subjects in the total vaccinated cohort with local/general symptoms sheets completed.
    Grade 2 = Local: painful when limb moved; General: interfered with normal activity.
    Grade 3 = Local/General: prevented normal activity.
    a Day of vaccination and the next 14 days.
    b Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
    c Oral temperatures.

    Adverse Reactions/Adverse Events

    BOOSTRIX

    (n = 1,480)

    %

    Tdap

    (n = 741)

    %

    Local

    Pain, any

    61.0

    69.2

    Pain, Grade 2 or 3

    35.1

    44.4

    Pain, Grade 3

    1.6

    2.3

    Redness, any

    21.1

    27.1

    Redness, >20 mm

    4.0

    6.2

    Redness, ≥50 mm

    1.6

    2.3

    Swelling, any

    17.6

    25.6

    Swelling, >20 mm

    3.9

    6.3

    Swelling, ≥50 mm

    1.4

    2.8

    General

    Headache, any

    30.1

    31.0

    Headache, Grade 2 or 3

    11.1

    10.5

    Headache, Grade 3

    2.2

    1.5

    Fatigue, any

    28.1

    28.9

    Fatigue, Grade 2 or 3

    9.1

    9.4

    Fatigue, Grade 3

    2.5

    1.2

    Gastrointestinal symptoms, anyb

    15.9

    17.5

    Gastrointestinal symptoms, Grade 2 or 3b

    4.3

    5.7

    Gastrointestinal symptoms, Grade 3b

    1.2

    1.3

    Fever, ≥99.5°F (37.5°C)c

    5.5

    8.0

    Fever, >100.4°F (38.0°C)c

    1.0

    1.5

    Fever, >102.2°F (39.0°C)c

    0.1

    0.4

    Unsolicited Adverse Events in the U.S. Adult (Aged 19 to 64 Years) Study

    The incidence of unsolicited adverse events reported in the 31 days after vaccination was comparable between the 2 groups (17.8% and 22.2% for BOOSTRIX and Tdap vaccine, respectively).

    Solicited Adverse Events in the U.S. Elderly (Aged 65 Years and Older) Study

    Table 4 presents solicited local adverse reactions and general adverse events within 4 days of vaccination with BOOSTRIX or the comparator Td vaccine for the total vaccinated cohort.

    Table 4. Rates of Solicited Local Adverse Reactions or General Adverse Events within 4 Daysa of Vaccination in the Elderly Aged 65 Years and Older (Total Vaccinated Cohort)
    Td = Tetanus and Diphtheria Toxoids Adsorbed, a U.S.-licensed Td vaccine, manufactured by Sanofi Pasteur.
    n = Number of subjects with a documented dose.
    Grade 2 = Local: painful when limb moved; General: interfered with normal activity.
    Grade 3 = Local/General: prevented normal activity.
    a Day of vaccination and the next 3 days.
    b Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
    c Oral temperatures.

    Adverse Reactions/Adverse Events

    BOOSTRIX

    %

    Td

    %

    Local

    (n = 882)

    (n = 444)

    Pain, any

    21.5

    27.7

    Pain, Grade 2 or 3

    7.5

    10.1

    Pain, Grade 3

    0.2

    0.7

    Redness, any

    10.8

    12.6

    Redness, >20 mm

    1.4

    2.5

    Redness, ≥50 mm

    0.6

    0.9

    Swelling, any

    7.5

    11.7

    Swelling, >20 mm

    2.2

    3.4

    Swelling, ≥50 mm

    0.7

    0.7

    General

    (n = 882)

    (n = 445)

    Fatigue, any

    12.5

    14.8

    Fatigue, Grade 2 or 3

    2.5

    2.9

    Fatigue, Grade 3

    0.7

    0.7

    Headache, any

    11.5

    11.7

    Headache, Grade 2 or 3

    1.9

    2.2

    Headache, Grade 3

    0.6

    0.0

    Gastrointestinal symptoms, anyb

    7.6

    9.2

    Gastrointestinal symptoms, Grade 2 or 3b

    1.7

    1.8

    Gastrointestinal symptoms, Grade 3b

    0.3

    0.4

    Fever, ≥99.5°F (37.5°C)c

    2.0

    2.5

    Fever, >100.4°F (38.0°C)c

    0.2

    0.2

    Fever, >102.2°F (39.0°C)c

    0.0

    0.0

    Unsolicited Adverse Events in the U.S. Elderly (Aged 65 Years and Older) Study

    The incidence of unsolicited adverse events reported in the 31 days after vaccination was comparable between the 2 groups (17.1% and 14.4% for BOOSTRIX and Td vaccine, respectively).

    Serious Adverse Events (SAEs)

    In the U.S. and German adolescent safety studies, no serious adverse events were reported to occur within 31 days of vaccination. During the 6-month extended safety evaluation period, no serious adverse events that were of potential autoimmune origin or new onset and chronic in nature were reported to occur. In non-U.S. adolescent studies in which serious adverse events were monitored for up to 37 days, 1 subject was diagnosed with insulin-dependent diabetes 20 days following administration of BOOSTRIX. No other serious adverse events of potential autoimmune origin or that were new onset and chronic in nature were reported to occur in these studies. In the U.S. adult (aged 19 to 64 years) study, serious adverse events were reported to occur during the entire study period (0-6 months) by 1.4% and 1.7% of subjects who received BOOSTRIX and the comparator Tdap vaccine, respectively. During the 6-month extended safety evaluation period, no serious adverse events of a neuroinflammatory nature or with information suggesting an autoimmune etiology were reported in subjects who received BOOSTRIX. In the U.S. elderly (aged 65 years and older) study, serious adverse events were reported to occur by 0.7% and 0.9% of subjects who received BOOSTRIX and the comparator Td vaccine, respectively, during the 31-day period after vaccination. Serious adverse events were reported to occur by 4.2% and 2.2% of subjects who received BOOSTRIX and the comparator Td vaccine, respectively, during the 6-month period after vaccination.

    Concomitant Vaccination with Meningococcal Conjugate Vaccine in Adolescents

    In a randomized study in the U.S., 1,341 adolescents (aged 11 to 18 years) received either BOOSTRIX administered concomitantly with MENACTRA (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), (Sanofi Pasteur), or each vaccine administered separately 1 month apart [see Drug Interactions (7.1), Clinical Studies (14.5)]. Safety was evaluated in 446 subjects who received BOOSTRIX administered concomitantly with meningococcal conjugate vaccine at different injection sites, 446 subjects who received BOOSTRIX followed by meningococcal conjugate vaccine 1 month later, and 449 subjects who received meningococcal conjugate vaccine followed by BOOSTRIX 1 month later. Solicited local adverse reactions and general adverse events were recorded on diary cards for 4 days (Days 0-3) following each vaccination. Unsolicited adverse events were monitored for the 31-day period following each vaccination (Days 0-30). Table 5 presents the percentages of subjects experiencing local reactions at the injection site for BOOSTRIX and solicited general events following BOOSTRIX. The incidence of unsolicited adverse events reported in the 31 days after any vaccination was similar following each dose of BOOSTRIX in all cohorts.

    Table 5. Rates of Solicited Local Adverse Reactions or General Adverse Events Reported within the 4-Day Post-Vaccination Period following Administration of BOOSTRIX in Individuals Aged 11 to 18 Years (Total Vaccinated Cohort)
    MCV4 = MENACTRA (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), Sanofi Pasteur.
    n = number of subjects in the total vaccinated cohort with local/general symptoms sheets completed.
    a BOOSTRIX+MCV4 = Concomitant vaccination with BOOSTRIX and MENACTRA.
    b BOOSTRIX→MCV4 = BOOSTRIX followed by MCV4 1 month later.
    c MCV4→BOOSTRIX = MCV4 followed by BOOSTRIX 1 month later.
    d Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
    e Oral temperatures.

    Adverse Reactions/Adverse Events

    BOOSTRIX+MCV4a

    (n = 441)

    %

    BOOSTRIXMCV4b

    (n = 432-433)

    %

    MCV4BOOSTRIXc

    (n = 441)

    %

    Local (at injection site for BOOSTRIX)

    Pain, any

    70.1

    70.4

    47.8

    Redness, any

    22.7

    25.7

    17.9

    Swelling, any

    17.7

    18.1

    12.0

    General (following administration of BOOSTRIX)

    Fatigue

    34.0

    32.1

    20.4

    Headache

    34.0

    30.7

    17.0

    Gastrointestinal symptomsd

    15.2

    14.5

    7.7

    Fever, ≥99.5°F (37.5°C)e

    5.2

    3.5

    2.3

    6.2 Postmarketing Experience

    In addition to reports in clinical trials for BOOSTRIX, the following adverse events have been identified in persons aged 10 years and older during postapproval use of BOOSTRIX worldwide. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

    Blood and Lymphatic System Disorders

    Lymphadenitis, lymphadenopathy.

    Immune System Disorders

    Allergic reactions, including anaphylactic and anaphylactoid reactions.

    Cardiac Disorders

    Myocarditis.

    General Disorders and Administration Site Conditions

    Extensive swelling of the injected limb, injection site induration, injection site inflammation, injection site mass, injection site pruritus, injection site nodule, injection site warmth, injection site reaction.

    Musculoskeletal and Connective Tissue Disorders

    Arthralgia, back pain, myalgia.

    Nervous System Disorders

    Convulsions (with and without fever), encephalitis, facial palsy, loss of consciousness, paresthesia, syncope.

    Skin and Subcutaneous Tissue Disorders

    Angioedema, exanthem, Henoch-Schönlein purpura, rash, urticaria.

  • 7 DRUG INTERACTIONS

    7.1 Concomitant Vaccine Administration

    BOOSTRIX was administered concomitantly with MENACTRA in a clinical study of subjects aged 11 to 18 years [see Clinical Studies (14.5)]. Post-vaccination geometric mean antibody concentrations (GMCs) to PRN were lower following BOOSTRIX administered concomitantly with meningococcal conjugate vaccine compared with BOOSTRIX administered first. It is not known if the efficacy of BOOSTRIX is affected by the reduced response to PRN.

    BOOSTRIX was administered concomitantly with FLUARIX (Influenza Virus Vaccine) in a clinical study of subjects aged 19 to 64 years [see Clinical Studies (14.5)]. Lower GMCs for antibodies to the pertussis antigens filamentous hemagglutinin (FHA) and PRN were observed when BOOSTRIX was administered concomitantly with FLUARIX as compared with BOOSTRIX alone. It is not known if the efficacy of BOOSTRIX is affected by the reduced response to FHA and PRN.

    When BOOSTRIX is administered concomitantly with other injectable vaccines or Tetanus Immune Globulin, they should be given with separate syringes and at different injection sites. BOOSTRIX should not be mixed with any other vaccine in the same syringe or vial.

    7.2 Immunosuppressive Therapies

    Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to BOOSTRIX.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Exposure Registry

    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BOOSTRIX during pregnancy. Healthcare providers are encouraged to register women by calling 1-888-452-9622.

    Risk Summary

    All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. There are no adequate and well-controlled studies of BOOSTRIX in pregnant women in the U.S.

    Available data suggest that the rates of major birth defects and miscarriage in women who received BOOSTRIX within 28 days prior to conception or during pregnancy are consistent with estimated background rates (see Data).

    A developmental toxicity study was performed in female rats administered INFANRIX prior to mating and BOOSTRIX during gestation, 0.1 mL at each occasion (a single human dose is 0.5 mL). In a second study, female rats were administered 0.2 mL of BOOSTRIX prior to mating and during the gestation and lactation period. In a third study, female New Zealand White rabbits were given 0.5 mL (full human dose) of BOOSTRIX (non-U.S. formulation) prior to mating and during gestation. These studies revealed no evidence of harm to the fetus due to BOOSTRIX. (See Data)

    Data

    Human Data: An assessment of data from the ongoing U.S. pregnancy registry over approximately 13 years (2005-2018) included 1,388 prospective reports of exposure to BOOSTRIX within 28 days prior to conception or during pregnancy. Of these reports, 240 had known pregnancy outcomes available. After excluding those with exposure in the third trimester (n = 186) and those with an unknown exposure timing (n = 9), there were 45 pregnancies with known outcomes with exposure within 28 days prior to conception through the second trimester. Outcomes among these prospectively followed pregnancies included 3 cases of miscarriage in women exposed in the first trimester and no major birth defects in infants born to women with exposure within 28 days prior to conception or during pregnancy.

    An assessment of spontaneous and postmarketing data through August 2018 included 595 prospective reports of exposure to non-U.S. formulations of BOOSTRIX/Tdap or BOOSTRIX-Polio/Tdap-IPV within 28 days prior to conception or during pregnancy. Of these reports, 146 had known pregnancy outcomes available. After excluding elective terminations (n = 3), those with exposure in the third trimester (n = 56), and those with an unknown exposure timing (n = 4), there were 83 pregnancies with known outcomes with exposure during the 28 days prior to conception through the second trimester. Outcomes among these prospectively followed pregnancies included 1 live infant with a major birth defect born to a woman with exposure during the first trimester, 1 stillbirth in a woman exposed in the first trimester, and 4 cases of miscarriage in women exposed in the first trimester.

    Animal Data: Developmental toxicity studies were performed in female rats and New Zealand White rabbits. In one study, female rats were administered 0.1 mL of INFANRIX (a single human dose is 0.5 mL) by intramuscular injection 30 days prior to mating and 0.1 mL of BOOSTRIX (a single human dose is 0.5 mL) by intramuscular injection on Gestation Days 6, 8, 11, and 15. The antigens in INFANRIX are the same as those in BOOSTRIX, but INFANRIX is formulated with higher quantities of these antigens. In a second study, female rats were administered 0.2 mL of BOOSTRIX by intramuscular injection 28 days and 14 days prior to mating, on Gestation Days 3, 8, 11, and 15, and on Lactation Day 7. In these studies, no adverse effects on embryo-fetal or pre-weaning development up to Postnatal Day 25 were observed; there were no fetal malformations or variations observed. In a third study, female New Zealand White rabbits were administered 0.5 mL (full human dose) of BOOSTRIX (non-U.S. formulation) by intramuscular injection on Premating Days -28 and -14 and on Gestation Days 3, 8, 11, 15, and 24. In this study, no adverse effects on embryo-fetal development related to BOOSTRIX were observed; postnatal development was not evaluated.

    8.2 Lactation

    Risk Summary

    It is not known whether the vaccine components of BOOSTRIX are excreted in human milk. Data are not available to assess the effect of administration of BOOSTRIX on breastfed infants or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BOOSTRIX and any potential adverse effects on the breastfed child from BOOSTRIX or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

    8.4 Pediatric Use

    BOOSTRIX is not indicated for use in children aged younger than 10 years. Safety and effectiveness of BOOSTRIX in this age group have not been established.

    8.5 Geriatric Use

    In clinical trials, 1,104 subjects aged 65 years and older received BOOSTRIX; of these subjects, 299 were aged 75 years and older. Adverse events following BOOSTRIX were similar in frequency to those reported with the comparator Td vaccine [see Adverse Reactions (6.1)].

  • 11 DESCRIPTION

    BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) is a noninfectious, sterile, vaccine for intramuscular administration. It contains tetanus toxoid, diphtheria toxoid, and pertussis antigens (inactivated pertussis toxin [PT] and formaldehyde-treated FHA and PRN). The antigens are the same as those in INFANRIX, but BOOSTRIX is formulated with reduced quantities of these antigens.

    Tetanus toxin is produced by growing Clostridium tetani in a modified Latham medium derived from bovine casein. The diphtheria toxin is produced by growing Corynebacterium diphtheriae in Fenton medium containing a bovine extract. The bovine materials used in these extracts are sourced from countries which the United States Department of Agriculture (USDA) has determined neither have nor are at risk of bovine spongiform encephalopathy (BSE). Both toxins are detoxified with formaldehyde, concentrated by ultrafiltration, and purified by precipitation, dialysis, and sterile filtration.

    The acellular pertussis antigens (PT, FHA, and PRN) are isolated from Bordetella pertussis culture grown in modified Stainer-Scholte liquid medium. PT and FHA are isolated from the fermentation broth; PRN is extracted from the cells by heat treatment and flocculation. The antigens are purified in successive chromatographic and precipitation steps. PT is detoxified using glutaraldehyde and formaldehyde. FHA and PRN are treated with formaldehyde.

    Each antigen is individually adsorbed onto aluminum hydroxide. Each 0.5-mL dose is formulated to contain 5 Lf of tetanus toxoid, 2.5 Lf of diphtheria toxoid, 8 mcg of inactivated PT, 8 mcg of FHA, and 2.5 mcg of PRN (69 kiloDalton outer membrane protein).

    Tetanus and diphtheria toxoid potency is determined by measuring the amount of neutralizing antitoxin in previously immunized guinea pigs. The potency of the acellular pertussis components (inactivated PT and formaldehyde-treated FHA and pertactin) is determined by enzyme-linked immunosorbent assay (ELISA) on sera from previously immunized mice.

    Each 0.5-mL dose contains aluminum hydroxide as adjuvant (not more than 0.39 mg aluminum by assay), 4.4 mg of sodium chloride, ≤100 mcg of residual formaldehyde, and ≤100 mcg of polysorbate 80 (Tween 80).

    BOOSTRIX is available in vials and prefilled syringes. The tip caps of the prefilled syringes contain natural rubber latex; the plungers are not made with natural rubber latex. The vial stoppers are not made with natural rubber latex.

    BOOSTRIX is formulated without preservatives.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Tetanus

    Tetanus is a condition manifested primarily by neuromuscular dysfunction caused by a potent exotoxin released by Clostridium tetani (C. tetani). Protection against disease is due to the development of neutralizing antibodies to the tetanus toxin. A serum tetanus antitoxin level of at least 0.01 IU/mL, measured by neutralization assays, is considered the minimum protective level.2 A level ≥0.1 IU/mL by ELISA has been considered as protective.

    Diphtheria

    Diphtheria is an acute toxin-mediated infectious disease caused by toxigenic strains of Corynebacterium diphtheriae (C. diphtheriae). Protection against disease is due to the development of neutralizing antibodies to the diphtheria toxin. A serum diphtheria antitoxin level of 0.01 IU/mL, measured by neutralization assays, is the lowest level giving some degree of protection; a level of 0.1 IU/mL by ELISA is regarded as protective.3 Diphtheria antitoxin levels ≥1.0 IU/mL by ELISA have been associated with long-term protection.3

    Pertussis

    Pertussis (whooping cough) is a disease of the respiratory tract caused by Bordetella pertussis (B. pertussis). The role of the different components produced by B. pertussis in either the pathogenesis of, or the immunity to, pertussis is not well understood.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    BOOSTRIX has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility in animals. Vaccination of female rabbits and rats with BOOSTRIX had no effect on fertility. [See Use in Specific Populations (8.1).]

  • 14 CLINICAL STUDIES

    The efficacy of the tetanus and diphtheria toxoid components of BOOSTRIX is based on the immunogenicity of the individual antigens compared with U.S.-licensed vaccines using established serologic correlates of protection. The efficacy of the pertussis components of BOOSTRIX was evaluated by comparison of the immune response of adolescents and adults following a single dose of BOOSTRIX to the immune response of infants following a 3-dose primary series of INFANRIX. In addition, the ability of BOOSTRIX to induce a booster response to each of the antigens was evaluated.

    14.1 Efficacy of INFANRIX

    The efficacy of a 3-dose primary series of INFANRIX in infants has been assessed in 2 clinical studies: A prospective efficacy trial conducted in Germany employing a household contact study design and a double-blind, randomized, active Diphtheria and Tetanus Toxoids (DT)-controlled trial conducted in Italy sponsored by the National Institutes of Health (NIH) (for details see INFANRIX prescribing information). Serological data from a subset of infants immunized with INFANRIX in the household contact study were compared with the sera of adolescents and adults immunized with BOOSTRIX [see Clinical Studies (14.2, 14.3)]. In the household contact study, the protective efficacy of INFANRIX in infants against WHO-defined pertussis (21 days or more of paroxysmal cough with infection confirmed by culture and/or serologic testing) was calculated to be 89% (95% CI: 77%, 95%). When the definition of pertussis was expanded to include clinically milder disease, with infection confirmed by culture and/or serologic testing, the efficacy of INFANRIX against ≥7 days of any cough was 67% (95% CI: 52%, 78%) and against ≥7 days of paroxysmal cough was 81% (95% CI: 68%, 89%) (for details see INFANRIX prescribing information).

    14.2 Immunological Evaluation in Adolescents

    In a multicenter, randomized, controlled study conducted in the United States, the immune responses to each of the antigens contained in BOOSTRIX were evaluated in sera obtained approximately 1 month after administration of a single dose of vaccine to adolescent subjects (aged 10 to 18 years). Of the subjects enrolled in this study, approximately 76% were aged 10 to 14 years and 24% were aged 15 to 18 years. Approximately 98% of participants in this study had received the recommended series of 4 or 5 doses of either DTwP or a combination of DTwP and DTaP in childhood. The racial/ethnic demographics were as follows: white 85.8%, black 5.7%, Hispanic 5.6%, Oriental 0.8%, and other 2.1%.

    Response to Tetanus and Diphtheria Toxoids

    The antibody responses to the tetanus and diphtheria toxoids of BOOSTRIX compared with Td vaccine are shown in Table 6. One month after a single dose, anti-tetanus and anti-diphtheria seroprotective rates (≥0.1 IU/mL by ELISA) and booster response rates were comparable between BOOSTRIX and the comparator Td vaccine.

    Table 6. Antibody Responses to Tetanus and Diphtheria Toxoids following BOOSTRIX Compared with Td Vaccine in Adolescents Aged 10 to 18 Years (ATP Cohort for Immunogenicity)
    Td = Tetanus and Diphtheria Toxoids, Adsorbed manufactured by MassBiologics.
    ATP = According-to-protocol; CI = Confidence Interval.
    a Measured by ELISA.
    b Booster response: In subjects with pre-vaccination <0.1 IU/mL, post-vaccination concentration ≥0.4 IU/mL. In subjects with pre-vaccination concentration ≥0.1 IU/mL, an increase of at least 4 times the pre-vaccination concentration.
    c Seroprotection rate or booster response rate to BOOSTRIX was non-inferior to Td (upper limit of 2-sided 95% CI on the difference for Td minus BOOSTRIX ≤10%).
    d Non-inferiority criteria not prospectively defined for this endpoint.

    Antibodies

    n

    % ≥0.1 IU/mLa

    (95% CI)

    % ≥1.0 IU/mLa

    (95% CI)

    % Booster Responseb

    (95% CI)

    Anti-tetanus

    BOOSTRIX

    2,469-2,516

        Pre-vaccination

    97.7 (97.1, 98.3)

    36.8 (34.9, 38.7)

        Post-vaccination

    100 (99.8, 100)c

    99.5 (99.1, 99.7)d

    89.7 (88.4, 90.8)c

    Td

    817-834

        Pre-vaccination

    96.8 (95.4, 97.9)

    39.9 (36.5, 43.4)

        Post-vaccination

    100 (99.6, 100)

    99.8 (99.1, 100)

    92.5 (90.5, 94.2)

    Anti-diphtheria

    BOOSTRIX

    2,463-2,515

        Pre-vaccination

    85.8 (84.3, 87.1)

    17.1 (15.6, 18.6)

        Post-vaccination

    99.9 (99.7, 100)c

    97.3 (96.6, 97.9)d

    90.6 (89.4, 91.7)c

    Td

    814-834

        Pre-vaccination

    84.8 (82.1, 87.2)

    19.5 (16.9, 22.4)

        Post-vaccination

    99.9 (99.3, 100)

    99.3 (98.4, 99.7)

    95.9 (94.4, 97.2)

    Response to Pertussis Antigens

    The booster response rates of adolescents to the pertussis antigens are shown in Table 7. For each of the pertussis antigens the lower limit of the 2-sided 95% CI for the percentage of subjects with a booster response exceeded the pre-defined lower limit of 80% for demonstration of an acceptable booster response.

    Table 7. Booster Responses to the Pertussis Antigens following BOOSTRIX in Adolescents Aged 10 to 18 Years (ATP Cohort for Immunogenicity)
    ATP = According-to-protocol; CI = Confidence Interval; PT = Pertussis toxin; FHA = Filamentous hemagglutinin; PRN = Pertactin.
    a Booster response: In initially seronegative subjects (<5 EL.U./mL), post-vaccination antibody concentrations ≥20 EL.U./mL. In initially seropositive subjects with pre-vaccination antibody concentrations ≥5 EL.U./mL and <20 EL.U./mL, an increase of at least 4 times the pre-vaccination antibody concentration. In initially seropositive subjects with pre-vaccination antibody concentrations ≥20 EL.U./mL, an increase of at least 2 times the pre-vaccination antibody concentration.

    Pertussis Antibodies

    n

    BOOSTRIX

    % Booster Responsea (95% CI)

    Anti-PT

    2,677

    84.5 (83.0, 85.9)

    Anti-FHA

    2,744

    95.1 (94.2, 95.9)

    Anti-PRN

    2,752

    95.4 (94.5, 96.1)

    The GMCs to each of the pertussis antigens 1 month following a single dose of BOOSTRIX in the U.S. adolescent study (N = 2,941 to 2,979) were compared with the GMCs observed in infants following a 3-dose primary series of INFANRIX administered at 3, 4, and 5 months of age (N = 631 to 2,884). Table 8 presents the results for the total immunogenicity cohort in both studies (vaccinated subjects with serology data available for at least 1 pertussis antigen; the majority of subjects in the study of INFANRIX had anti-PT serology data only). These infants were a subset of those who formed the cohort for the German household contact study in which the efficacy of INFANRIX was demonstrated [see Clinical Studies (14.1)]. Although a serologic correlate of protection for pertussis has not been established, anti-PT, anti-FHA, and anti-PRN antibody concentrations observed in adolescents 1 month after a single dose of BOOSTRIX were non-inferior to those observed in infants following a primary vaccination series with INFANRIX.

    Table 8. Ratio of GMCs to Pertussis Antigens following 1 Dose of BOOSTRIX in Adolescents Aged 10 to 18 Years Compared with 3 Doses of INFANRIX in Infants (Total Immunogenicity Cohort)
    GMC = Geometric mean antibody concentration, measured in ELISA units; CI = Confidence Interval; PT = Pertussis toxin; FHA = Filamentous hemagglutinin; PRN = Pertactin.
    Number of subjects for GMC evaluation for BOOSTRIX: Anti-PT = 2,941, anti-FHA = 2,979, and anti-PRN = 2,978.
    Number of subjects for GMC evaluation for INFANRIX: Anti-PT = 2,884, anti-FHA = 685, and anti-PRN = 631.
    a GMC following BOOSTRIX was non-inferior to GMC following INFANRIX (lower limit of 95% CI for the GMC ratio of BOOSTRIX/INFANRIX >0.67).

    Pertussis Antibodies

    GMC Ratio: BOOSTRIX/INFANRIX

    (95% CI)

    Anti-PT

    1.90 (1.82, 1.99)a

    Anti-FHA

    7.35 (6.85, 7.89)a

    Anti-PRN

    4.19 (3.73, 4.71)a

    14.3 Immunological Evaluation in Adults (Aged 19 to 64 Years)

    A multicenter, randomized, observer-blinded study, conducted in the United States, evaluated the immunogenicity of BOOSTRIX compared with the licensed comparator Tdap vaccine (Sanofi Pasteur). Vaccines were administered as a single dose to subjects (N = 2,284) who had not received a tetanus-diphtheria booster within 5 years. The immune responses to each of the antigens contained in BOOSTRIX were evaluated in sera obtained approximately 1 month after administration. Approximately 33% of patients were aged 19 to 29 years, 33% were aged 30 to 49 years, and 34% were aged 50 to 64 years. Among subjects in the combined vaccine groups, 62% were female; 84% of subjects were white, 8% black, 1% Asian, and 7% were of other racial/ethnic groups.

    Response to Tetanus and Diphtheria Toxoids

    The antibody responses to the tetanus and diphtheria toxoids of BOOSTRIX compared with the comparator Tdap vaccine are shown in Table 9. One month after a single dose, anti-tetanus and anti-diphtheria seroprotective rates (≥0.1 IU/mL by ELISA) were comparable between BOOSTRIX and the comparator Tdap vaccine.

    Table 9. Antibody Responses to Tetanus and Diphtheria Toxoids following 1 Dose of BOOSTRIX Compared with the Comparator Tdap Vaccine in Adults Aged 19 to 64 Years (ATP Cohort for Immunogenicity)
    Tdap = Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed manufactured by Sanofi Pasteur.
    ATP = According-to-protocol; CI = Confidence Interval.
    a Measured by ELISA.
    b Seroprotection rates for BOOSTRIX were non-inferior to the comparator Tdap vaccine (lower limit of 95% CI on the difference of BOOSTRIX minus Tdap ≥-10%).
    c Non-inferiority criteria not prospectively defined for this endpoint.

    Antibodies

    n

    % ≥0.1 IU/mLa

    (95% CI)

    % ≥1.0 IU/mLa

    (95% CI)

    Anti-tetanus

    BOOSTRIX

    1,445-1,447

        Pre-vaccination

    95.9 (94.8, 96.9)

    71.9 (69.5, 74.2)

        Post-vaccination

    99.6 (99.1, 99.8)b

    98.3 (97.5, 98.9)b

    Tdap

    727-728

        Pre-vaccination

    97.2 (95.8, 98.3)

    74.7 (71.4, 77.8)

        Post-vaccination

    100 (95.5, 100)

    99.3 (98.4, 99.8)

    Anti-diphtheria

    BOOSTRIX

    1,440-1,444

        Pre-vaccination

    85.2 (83.3, 87.0)

    23.7 (21.5, 26.0)

        Post-vaccination

    98.2 (97.4, 98.8)b

    87.9 (86.1, 89.5)c

    Tdap

    720-727

        Pre-vaccination

    89.2 (86.7, 91.3)

    26.5 (23.3, 29.9)

        Post-vaccination

    98.6 (97.5, 99.3)

    92.0 (89.8, 93.9)

    Response to Pertussis Antigens

    Booster response rates to the pertussis antigens are shown in Table 10. For the FHA and PRN antigens, the lower limit of the 95% CI for the booster responses exceeded the pre-defined limit of 80% demonstrating an acceptable booster response following BOOSTRIX. The PT antigen booster response lower limit of the 95% CI (74.9%) did not exceed the pre-defined limit of 80%.

    Table 10. Booster Responses to the Pertussis Antigens following 1 Dose of BOOSTRIX in Adults Aged 19 to 64 Years (ATP Cohort for Immunogenicity)
    ATP = According-to-protocol; CI = Confidence Interval; PT = Pertussis toxin; FHA = Filamentous hemagglutinin; PRN = Pertactin.
    a Booster response: In initially seronegative subjects (<5 EL.U./mL), post-vaccination antibody concentrations ≥20 EL.U./mL. In initially seropositive subjects with pre-vaccination antibody concentrations ≥5 EL.U./mL and <20 EL.U./mL, an increase of at least 4 times the pre-vaccination antibody concentration. In initially seropositive subjects with pre-vaccination antibody concentrations ≥20 EL.U./mL, an increase of at least 2 times the pre-vaccination antibody concentration.
    b The PT antigen booster response lower limit of the 95% CI did not exceed the pre-defined limit of 80%.
    c The FHA and PRN antigens booster response lower limit of the 95% CI exceeded the pre-defined limit of 80%.

    Pertussis Antibodies

    n

    BOOSTRIX

    % Booster Responsea

    (95% CI)

    Anti-PT

    1,419

    77.2 (74.9, 79.3)b

    Anti-FHA

    1,433

    96.9 (95.8, 97.7)c

    Anti-PRN

    1,441

    93.2 (91.8, 94.4)c

    The GMCs to each of the pertussis antigens 1 month following a single dose of BOOSTRIX in the U.S. adult (aged 19 to 64 years) study were compared with the GMCs observed in infants following a 3-dose primary series of INFANRIX administered at 3, 4, and 5 months of age. Table 11 presents the results for the total immunogenicity cohort in both studies (vaccinated subjects with serology data available for at least 1 pertussis antigen). These infants were a subset of those who formed the cohort for the German household contact study in which the efficacy of INFANRIX was demonstrated [see Clinical Studies (14.1)]. Although a serologic correlate of protection for pertussis has not been established, anti-PT, anti-FHA, and anti-PRN antibody concentrations observed in adults 1 month after a single dose of BOOSTRIX were non-inferior to those observed in infants following a primary vaccination series with INFANRIX.

    Table 11. Ratio of GMCs to Pertussis Antigens following 1 Dose of BOOSTRIX in Adults Aged 19 to 64 Years Compared with 3 Doses of INFANRIX in Infants (Total Immunogenicity Cohort)
    GMC = Geometric mean antibody concentration; CI = Confidence Interval; PT = Pertussis toxin; FHA = Filamentous hemagglutinin; PRN = Pertactin.
    Number of subjects for GMC evaluation for BOOSTRIX: Anti-PT = 1,460, anti-FHA = 1,472, and anti-PRN = 1,473.
    Number of subjects for GMC evaluation for INFANRIX: Anti-PT = 2,884, anti-FHA = 685, and anti-PRN = 631.
    a BOOSTRIX was non-inferior to INFANRIX (lower limit of 95% CI for the GMC ratio of BOOSTRIX/INFANRIX ≥0.67).

    Pertussis Antibodies

    GMC Ratio: BOOSTRIX/INFANRIX

    (95% CI)

    Anti-PT

    1.39 (1.32, 1.47)a

    Anti-FHA

    7.46 (6.86, 8.12)a

    Anti-PRN

    3.56 (3.10, 4.08)a

    14.4 Immunological Evaluation in the Elderly (Aged 65 Years and Older)

    The U.S. elderly (aged 65 years and older) study, a randomized, observer-blinded study, evaluated the immunogenicity of BOOSTRIX (n = 887) compared with a U.S.-licensed comparator Td vaccine (n = 445) (Sanofi Pasteur). Vaccines were administered as a single dose to subjects who had not received a tetanus-diphtheria booster within 5 years. Among all vaccine recipients, the mean age was approximately 72 years; 54% were female and 95% were white. The immune responses to each of the antigens contained in BOOSTRIX were evaluated in sera obtained approximately 1 month after administration.

    Response to Tetanus and Diphtheria Toxoids and Pertussis Antigens

    Immune responses to tetanus and diphtheria toxoids and pertussis antigens were measured 1 month after administration of a single dose of BOOSTRIX or a comparator Td vaccine. Anti-tetanus and anti-diphtheria seroprotective rates (≥0.1 IU/mL) were comparable between BOOSTRIX and the comparator Td vaccine (Table 12).

    Table 12. Immune Responses to Tetanus and Diphtheria Toxoids following BOOSTRIX or Comparator Td Vaccine in the Elderly Aged 65 Years and Older (ATP Cohort for Immunogenicity)
    Td = Tetanus and Diphtheria Toxoids Adsorbed, a U.S.-licensed Td vaccine, manufactured by Sanofi Pasteur.
    ATP = According-to-protocol; CI = Confidence Interval.
    a Seroprotection rates for BOOSTRIX were non-inferior to the comparator Td vaccine (lower limit of 95% CI on the difference of BOOSTRIX minus Td ≥-10%).
    b Non-inferiority criteria not prospectively defined for this endpoint.

    Anti-Tetanus and Anti-Diphtheria Titers

    BOOSTRIX

    Td

    (n = 844-864)

    (n = 430-439)

    Anti-tetanus

       % ≥0.1 IU/mL (95% CI)

    96.8 (95.4, 97.8)a

    97.5 (95.6, 98.7)

       % ≥1.0 IU/mL (95% CI)

    88.8 (86.5, 90.8)a

    90.0 (86.8, 92.6)

    Anti-diphtheria

       % ≥0.1 IU/mL (95% CI)

    84.9 (82.3, 87.2)a

    86.6 (83.0, 89.6)

       % ≥1.0 IU/mL (95% CI)

    52.0 (48.6, 55.4)b

    51.2 (46.3, 56.0)

    The GMCs to each of the pertussis antigens 1 month following a single dose of BOOSTRIX were compared with the GMCs of infants following a 3-dose primary series of INFANRIX administered at 3, 4, and 5 months of age. Table 13 presents the results for the total immunogenicity cohort in both studies (vaccinated subjects with serology data available for at least 1 pertussis antigen). These infants were a subset of those who formed the cohort for the German household contact study in which the efficacy of INFANRIX was demonstrated [see Clinical Studies (14.1)]. Although a serologic correlate of protection for pertussis has not been established, anti-PT, anti-FHA, and anti-PRN antibody concentrations in the elderly (aged 65 years and older) 1 month after a single dose of BOOSTRIX were non-inferior to those of infants following a primary vaccination series with INFANRIX.

    Table 13. Ratio of GMCs to Pertussis Antigens following 1 Dose of BOOSTRIX in the Elderly Aged 65 Years and Older Compared with 3 Doses of INFANRIX in Infants (Total Immunogenicity Cohort)
    GMC = Geometric mean antibody concentration; CI = Confidence Interval; PT = Pertussis toxin; FHA = Filamentous hemagglutinin; PRN = Pertactin.
    Number of subjects for GMC evaluation for BOOSTRIX: Anti-PT = 865, anti-FHA = 847, and anti-PRN = 878.
    Number of subjects for GMC evaluation for INFANRIX: Anti-PT = 2,884, anti-FHA = 685, and anti-PRN = 631.
    a BOOSTRIX was non-inferior to INFANRIX (lower limit of 95% CI for the GMC ratio of BOOSTRIX/INFANRIX ≥0.67).

    Pertussis Antibodies

    GMC Ratio: BOOSTRIX/INFANRIX

    (95% CI)

    Anti-PT

    1.07 (1.00, 1.15)a

    Anti-FHA

    8.24 (7.45, 9.12)a

    Anti-PRN

    0.93 (0.79, 1.10)a

    14.5 Concomitant Vaccine Administration

    Concomitant Administration with Meningococcal Conjugate Vaccine

    The concomitant use of BOOSTRIX and a tetravalent meningococcal (groups A, C, Y, and W-135) conjugate vaccine (Sanofi Pasteur) was evaluated in a randomized study in healthy adolescents aged 11 to 18 years. A total of 1,341 adolescents were vaccinated with BOOSTRIX. Of these, 446 subjects received BOOSTRIX administered concomitantly with meningococcal conjugate vaccine at different injection sites, 446 subjects received BOOSTRIX followed by meningococcal conjugate vaccine 1 month later, and 449 subjects received meningococcal conjugate vaccine followed by BOOSTRIX 1 month later.

    Immune responses to diphtheria and tetanus toxoids (% of subjects with anti-tetanus and anti-diphtheria antibodies ≥1.0 IU/mL by ELISA), pertussis antigens (booster responses and GMCs), and meningococcal antigens (vaccine responses) were measured 1 month (range: 30 to 48 days) after concomitant or separate administration of BOOSTRIX and meningococcal conjugate vaccine. For BOOSTRIX given concomitantly with meningococcal conjugate vaccine compared with BOOSTRIX administered first, non-inferiority was demonstrated for all antigens, with the exception of the anti-PRN GMC. The lower limit of the 95% CI for the GMC ratio was 0.54 for anti-PRN (pre-specified limit ≥0.67). For the anti-PRN booster response, non-inferiority was demonstrated. It is not known if the efficacy of BOOSTRIX is affected by the reduced response to PRN.

    There was no evidence that BOOSTRIX interfered with the antibody responses to the meningococcal antigens when measured by rabbit serum bactericidal assays (rSBA) when given concomitantly or sequentially (meningococcal conjugate vaccine followed by BOOSTRIX or BOOSTRIX followed by meningococcal conjugate vaccine).

    Concomitant Administration with FLUARIX (Influenza Virus Vaccine)

    The concomitant use of BOOSTRIX and FLUARIX was evaluated in a multicenter, open-label, randomized, controlled study of 1,497 adults aged 19 to 64 years. In one group, subjects received BOOSTRIX and FLUARIX concurrently (n = 748). The other group received FLUARIX at the first visit, then 1 month later received BOOSTRIX (n = 749). Sera was obtained prior to and 1 month following concomitant or separate administration of BOOSTRIX and/or FLUARIX, as well as 1 month after the separate administration of FLUARIX.

    Immune responses following concurrent administration of BOOSTRIX and FLUARIX were non-inferior to separate administration for diphtheria (seroprotection defined as ≥0.1 IU/mL), tetanus (seroprotection defined as ≥0.1 IU/mL and based on concentrations ≥1.0 IU/mL), PT antigen (anti-PT GMC) and influenza antigens (percent of subjects with hemagglutination-inhibition [HI] antibody titer ≥1:40 and ≥4-fold rise in HI titer). Non-inferiority criteria were not met for the anti-pertussis antigens FHA and PRN. The lower limit of the 95% CI of the GMC ratio was 0.64 for anti-FHA and 0.60 for anti-PRN and the pre-specified limit was ≥0.67. It is not known if the efficacy of BOOSTRIX is affected by the reduced response to FHA and PRN.

  • 15 REFERENCES

    1.
    Institute of Medicine (IOM). Stratton KR, Howe CJ, Johnston RB, eds. Adverse events associated with childhood vaccines. Evidence bearing on causality. Washington, DC: National Academy Press; 1994.
    2.
    Wassilak SGF, Roper MH, Kretsinger K, and Orenstein WA. Tetanus Toxoid. In: Plotkin SA, Orenstein WA, and Offit PA, eds. Vaccines. 5th ed. Saunders; 2008:805-839.
    3.
    Vitek CR and Wharton M. Diphtheria Toxoid. In: Plotkin SA, Orenstein WA, and Offit PA, eds. Vaccines. 5th ed. Saunders; 2008:139-156.
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    BOOSTRIX is available in 0.5-mL single-dose vials and single-dose, disposable, prefilled TIP-LOK syringes (packaged without needles):

    NDC 58160-842-01 Vial in Package of 10: NDC 58160-842-11

    NDC 58160-842-05 Syringe in Package of 1: NDC 58160-842-34

    NDC 58160-842-43 Syringe in Package of 10: NDC 58160-842-52

    Store refrigerated between 2º and 8ºC (36º and 46ºF). Do not freeze. Discard if the vaccine has been frozen.

  • 17 PATIENT COUNSELING INFORMATION

    Provide the following information to the vaccine recipient, parent, or guardian:

    Inform of the potential benefits and risks of immunization with BOOSTRIX.
    Inform about the potential for adverse reactions that have been temporally associated with administration of BOOSTRIX or other vaccines containing similar components.
    Instruct vaccine recipient to report any adverse events to their healthcare provider.
    Advise women who receive BOOSTRIX during pregnancy to enroll in the pregnancy registry [see Use in Specific Populations (8.1)].
    Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
  • SPL UNCLASSIFIED SECTION

    BOOSTRIX, FLUARIX, INFANRIX, and TIP‑LOK are trademarks owned by or licensed to the GSK group of companies. The other brands listed are trademarks owned by or licensed to their respective owners and are not owned by or licensed to the GSK group of companies. The makers of these brands are not affiliated with and do not endorse the GSK group of companies or its products.

    Manufactured by GlaxoSmithKline Biologicals

    Rixensart, Belgium, U.S. License 1617, and

    GSK Vaccines GmbH

    Marburg, Germany, U.S. License 1617

    Distributed by GlaxoSmithKline

    Research Triangle Park, NC 27709

    ©2019 GSK group of companies or its licensor.

    BTX:31PI

  • PRINCIPAL DISPLAY PANEL

    PRINCIPAL DISPLAY PANEL

    NDC 58160-842-11

    BOOSTRIX

    Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed

    Tdap

    Rx only

    For 10 Years of Age and Older

    10 x 0.5-mL Single-Dose Vials

    Made in Belgium

    ©2019 the GSK group of companies or its licensor.

     
    496044 Rev. 2/19
    Boostrix 10 count carton
  • INGREDIENTS AND APPEARANCE
    BOOSTRIX 
    tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed suspension
    Product Information
    Product TypeVACCINEItem Code (Source)NDC:58160-842
    Route of AdministrationINTRAMUSCULAR
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: K3W1N8YP13) (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:K3W1N8YP13) CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)5 [iU]  in 0.5 mL
    CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: IRH51QN26H) (CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:IRH51QN26H) CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)2.5 [iU]  in 0.5 mL
    BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) (UNII: QSN5XO8ZSU) (BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) - UNII:QSN5XO8ZSU) BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED)8 ug  in 0.5 mL
    BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: 8C367IY4EY) (BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:8C367IY4EY) BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)8 ug  in 0.5 mL
    BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) (UNII: I05O535NV6) (BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) - UNII:I05O535NV6) BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED)2.5 ug  in 0.5 mL
    Inactive Ingredients
    Ingredient NameStrength
    ALUMINUM HYDROXIDE (UNII: 5QB0T2IUN0)  
    FORMALDEHYDE (UNII: 1HG84L3525)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:58160-842-1110 in 1 CARTON
    1NDC:58160-842-010.5 mL in 1 VIAL; Type 0: Not a Combination Product
    2NDC:58160-842-5210 in 1 CARTON
    2NDC:58160-842-430.5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    3NDC:58160-842-341 in 1 CARTON
    3NDC:58160-842-050.5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12510607/24/2009
    Labeler - GlaxoSmithKline Biologicals SA (372748392)